Get the Stockscreener App
13.48
0.37%
-0.05
Syndax Pharmaceuticals Inc stock is traded at $13.48, with a volume of 960.12K.
It is down -0.37% in the last 24 hours and down -25.48% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$13.53
Open:
$13.58
24h Volume:
960.12K
Relative Volume:
0.41
Market Cap:
$1.20B
Revenue:
$217.42M
Net Income/Loss:
$-243.25M
P/E Ratio:
-4.8226
EPS:
-2.7952
Net Cash Flow:
$-278.35M
1W Performance:
-20.24%
1M Performance:
-25.48%
6M Performance:
-44.60%
1Y Performance:
-10.37%
1-Day Range:
$13.44
$14.05
1-Week Range:
$13.39
$17.42
52-Week Range:
$12.99
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.48 | 1.20B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? - Simply Wall Street
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - TradingView
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PR Newswire
Syndax Pharmaceuticals Suffers Pipeline BlowSyndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $37.27, Implies 125% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownHere's What Happened - MarketBeat
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. - Barron's
Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed as Buy by HC Wainwright - MarketBeat
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? - Yahoo Finance
Syndax Pharmaceuticals ends IPF development after Phase 2 axatilimab miss - Mugglehead Investment Magazine
SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Yahoo Finance
Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria - GuruFocus
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development - Yahoo Finance
Syndax Pharmaceuticals stock tumbles on failed IPF trial - Yahoo Finance
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewswire
Possible Bearish Signals With Syndax Pharmaceuticals Insiders Disposing Stock - Moomoo
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Cash flow from investing activities of Syndax Pharmaceuticals Inc – HAN:1T3 - TradingView
Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX) - Seeking Alpha
Syndax Pharmaceuticals poised for growth with p... - Pluang
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors - BioWorld News
Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Inc. (SNDX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Syndax stock gains attention as investor conferences approach - ad-hoc-news.de
Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
(SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Syndax Pharmaceuticals Inc Stock (SNDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Jul 08 '26 |
Sale |
24.24 |
32,375 |
784,776 |
484,843 |
| MICHAEL METZGER | Director |
Jul 08 '26 |
Proposed Sale |
23.24 |
32,375 |
752,395 |
0 |
| Botwood Nicholas A.J. | Officer |
Jun 12 '26 |
Proposed Sale |
18.14 |
31,235 |
566,693 |
0 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Sale |
18.14 |
31,235 |
566,603 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Option Exercise |
13.82 |
31,235 |
431,668 |
92,120 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Sale |
18.00 |
34,280 |
617,040 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Option Exercise |
13.82 |
22,515 |
311,157 |
95,165 |
| Botwood Nicholas A.J. | Officer |
Jun 11 '26 |
Proposed Sale |
17.78 |
34,280 |
609,435 |
0 |
| Goldan Keith A. | Chief Financial Officer |
Jun 01 '26 |
Sale |
18.99 |
1,177 |
22,351 |
139,252 |
| Metzger Michael A | Chief Executive Officer |
Jun 01 '26 |
Sale |
18.99 |
6,847 |
130,025 |
484,843 |
2.59%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):